Literature DB >> 50345

Demonstration of a tumor-associated surface antigen in Marek's disease.

R L Witter, E A Stephens, J M Sharma, K Nazerian.   

Abstract

Surface antigenic markers were detected on three classes of Marek's disease (MD) tumor cells, i.e., MD lymphoma cells, cultured cells of the MSB-1 lymphoblastoid cell line, and JMV lymphoblastic leukemia cells, by indirect membrane immunofluorescent staining with serum from chickens immunized with JMV cells or from rabbits immunized with MSB-1 cells. This surface antigen was not detected on normal chicken lymphocytes, RPL-16 tumor cells (tranedormed by an avian RNA virus, or MD virus-infected fibroblasts that were positive for viral membrane antigen (MA). Furthermore, the surface antigen appeared unrelated to embryonic or histocompatibility antigens. This antigen is provisionally designated as a Marek's disease tumor-associated surface antigen (MATSA). The MATSA's on JMV, MSB-1 and MD lymphoma cells were related but not identical as demonstrated by antiserum titration, absorption and blocking tests with homologous and heterologous systems.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50345

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).

Authors:  S C Burgess; J R Young; B J G Baaten; L Hunt; L N J Ross; M S Parcells; P M Kumar; C A Tregaskes; L F Lee; T F Davison
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-08       Impact factor: 11.205

2.  Comparative effects of host and viral factors on early pathogenesis of Marek's disease.

Authors:  J Fabricant; M Ianconescu; B W Calnek
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Pathogenesis of Marek's disease; effect of immunization with inactivated viral and tumor-associated antigens.

Authors:  K K Murthy; B W Calnek
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

4.  In vitro establishment of Marek's disease herpesvirus-transformed productive and nonproductive lymphoblastoid cell lines.

Authors:  D Munch; L Hohlstein; M Sevoian
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

5.  Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.

Authors:  J M Sharma
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

6.  Protection against Marek's disease-derived tumor transplants by the nononcogenic SB-1 strain of Marek's disease virus.

Authors:  K A Schat; B W Calnek
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

7.  Marke's disease herpesviruses. III. Purification and characterization of Marek's disease herpesvirus B antigen.

Authors:  L F Velicer; D R Yager; J L Clark
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

8.  Natural killer cell activity in chickens: target cell analysis and effect of antithymocyte serum on effector cells.

Authors:  J M Sharma; W Okazaki
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  Development and characterization of monoclonal antibodies to Marek's disease tumor-associated surface antigen.

Authors:  X F Liu; L F Lee
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

10.  Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.

Authors:  Shane C Burgess; T Fred Davison
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.